Molecular evolution using the tools of phage, yeast, mammalian, antibody, and other display methods have yielded a staggering array of monoclonal and multi-specific antibodies, antibody-drug conjugates, immunotherapies, and numerous other constructs.
The emergence of computational tools will be applied to improve selection, design, and efficacy of candidates. Conditional activation approaches will allow drug molecules to hit the tumour before they become activated, reducing off-target toxicity,
and adverse events. Strategies to develop synthetic libraries and in vivo selection will be explored, along with the use of phage display to alter the functional activity of antibodies.